AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY

AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY - Azelnidipine/ARB & Sympathetic activity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009158

Enrollment

Registered

2012-10-21

Start date

2012-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD)

Interventions

concurrent treatment with olmesartan and azelnidipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with CKD undergoing treatment with olmesartan for at least 2 months before enrollment no medication with calcium channel blockers for at least 2 months before enrollment

Exclusion criteria

Exclusion criteria: 1) polycystic kidney disease 2) arrhythmia 3) known history of angina pectoris, myocardial infarction, heart failure, stroke, or TIA

Design outcomes

Primary

Measure	Time frame
Decrease in LF/HF, increase in HF and the attenuation of the non-Gaussianity index during 8-wk treatment with ARB/CCB	—

Secondary

Measure	Time frame
changes in proteinuria (mg/gCre) and office blood pressure	—

Countries

Japan

Contacts

Public ContactMichio FUKUDA

Nagoya City University Hospital Division of Nephrology

m-fukuda@med.nagoya-cu.ac.jp81-52-853-8221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026